Low-dose metformin for symptoms of fibromyalgia
Tests metformin against placebo for symptoms in adults with fibromyalgia.
Key facts
- Who runs it
- University of Utah
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Registry title
- Metformin for Fibromyalgia Symptoms (INFORM Trial)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 72 people, planned
- Started
- 1 Apr 2023
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Metformin
- Placebo
- Record updated
- 30 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with fibromyalgia to test low-dose metformin against a placebo (dummy pill) for 8 weeks.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Fibromyalgia that meets the American College of Rheumatology 2016 revised classification criteria.
- Earlier treatment
- People taking weight-control medicines (for example Xenical) cannot join.
- Biomarker or test result
- Creatinine, vitamin B12 and liver test results must be normal. eGFR (a kidney test) must not be below 45mL/min/1.73m2.
Main reasons for not taking part
- Diabetes
- Pregnancy, or planning a pregnancy in the next year
- Known heart, liver, kidney or lung disease, or another worsening disease
- Autoimmune disease such as rheumatoid arthritis, or nerve pain
- Serious mental illness or recent substance abuse
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- To be able to follow the protocol in English
- Fibromyalgia Syndrome: Participant must meet the American College of Rheumatology 2016 revised classification criteria for Fibromyalgia
- Ability to take oral medication and be willing to adhere to the metformin regimen (once daily)
Who cannot take part
- Concurrent use of weight controlling medications (eg, Xenical)
- Co-occurring progressive disease (self-report, physician-diagnosed)
- Diabetes
- Having known cardiovascular, liver, kidney or pulmonary diseases (self-report, physician-diagnosed)
- Having known serious psychopathology (Clinician diagnoses of psychosis, organic mental disorder, or dissociative disorder, self-reported active suicidal intent, self-reported history of inpatient admission to a psychiatric ward in the past year, evidence or self-report of self-injurious behaviors in the past year, reported current or recent history (2years) of non-IV substance abuse, any history of recreational IV drug use)
- Having autoimmune disorder (e.g., rheumatoid arthritis) (self-report, physician-diagnosed)
- Having pain associated with a terminal illness, acute pain, pain associated with specific organ damage (eg, stomach ulcer) (self-report, physician-diagnosed)
- Abnormal levels of creatinine, vitamin B12, or hepatic function panel
- eGFR of below 45mL/min/1.73m2
- Pregnancy or planning to be pregnant in the next year (all premenopausal participants will be tested)
- Having neuropathic pain (self-report, physician-diagnosed)
- Requiring an interpreter to communicate
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of UtahSalt Lake City, United StatesContact: Reiko Mitsunaga, RNTaking people
About the trial
What the trial wants to find out
The main purpose of the project is to evaluate the safety and efficacy of low dose metformin for improving symptoms associated with fibromyalgia syndrome (FMS) via modulating neuroinflammatory pathways. The investigators hypothesize that FMS patients in the low-dose metformin conditions will show greater improvement in FMS symptoms than those who are in the placebo group. Further, the investigators hypothesize that metformin will increase phosphorylated AMPK in peripheral immune cells of FMS patients and will decrease the transcription of mTORC1, NLRP3 inflammasome, and nociceptive cytokines interleukin 1beta and interleukin 18.
The 2 groups in the trial
- 1: Metformin TreatmentExisting treatment, for comparison
500 mg metformin ER tablets once daily in the morning with a glass of water for 8 weeks.
Treatment: Metformin
- 2: PlaceboPlacebo, for comparison
Matching metformin ER placebo tablets once daily in the morning with a glass of water for 8 weeks.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Metformin as a Novel, Mechanistic Treatment of Fibromyalgia; a Proof of Concept RCT
- Plain-language title
- Low-dose metformin for symptoms of fibromyalgiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05900466, who can take part
- Record updated
- 30 March 2026